Codeine Shortages Hit New Zealand Pharmacies Amidst Shipping Woes
Pharmacies across Aotearoa are currently grappling with a significant shortage of the prescription-only painkiller codeine, a situation exacerbated by ongoing shipping delays. Pharmac, the country's drug-funding agency, has confirmed that the supply issue is impacting all three strengths of the subsidised Noumed brand of codeine.
The next anticipated shipment was initially slated for arrival in mid-November. However, it appears that even once the stock lands, it could take an additional one to two weeks for these much-needed medications to reach pharmacy shelves nationwide. This delay means that some patients may face difficulties in obtaining their prescribed pain relief.
Pharmac has indicated that at present, there is no stock of the 30mg codeine tablets available. Furthermore, supplies of both the 15mg and 60mg strengths are critically low. This widespread scarcity is causing concern for both healthcare professionals and those relying on codeine for managing their pain conditions.
Addressing the Supply Gap: Over-Labelling Initiative
In an effort to mitigate the impact of the current shortages, a temporary measure is being implemented involving the distribution of some existing supplies of 15mg and 30mg codeine tablets. These particular batches are being dispatched to wholesalers this week after undergoing a re-labelling process to reflect an updated expiry date.
Historically, codeine tablets available in New Zealand carried a shelf-life of 24 months from the date of manufacture. However, this timeframe was extended to 36 months in July of this year. This change in regulation prompted the supplier to hold stock that was originally labelled with the shorter, 24-month expiry period.
Pharmac explained that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, expedited the approval process for an "over-labelling" initiative. This process allows the existing stock to be re-labelled with the new, extended 36-month shelf-life, thereby ensuring that patients continue to have access to this essential medicine.
The distribution of this over-labelled stock to wholesalers is expected to commence by the close of this week. To ensure transparency and to allay any potential patient concerns, Pharmac has prepared a dedicated information flyer. This flyer aims to reassure individuals that the over-labelled product is both safe and effective for use, adhering to the updated shelf-life guidelines.
The current situation highlights the vulnerability of New Zealand's medicine supply chain to global disruptions. Such shortages can have a profound impact on individuals managing chronic pain or recovering from injuries, underscoring the importance of robust supply management and contingency planning.
The wider implications of medicine supply chain fragility have been a topic of recent discussion. Studies have previously warned that New Zealand could be at risk of running out of certain essential medicines if unforeseen global catastrophes were to occur. This current codeine shortage serves as a stark reminder of these underlying vulnerabilities.
In related health news, there have also been recent efforts to highlight the dangers associated with the overuse or misuse of common painkillers like paracetamol, underscoring the need for informed and responsible medication practices.
The ongoing codeine shortage is a complex issue with multiple contributing factors, from international shipping logistics to regulatory changes and the subsequent implementation of solutions. While the over-labelling initiative offers some immediate relief, the long-term security of prescription medicine supplies remains a critical focus for healthcare authorities in New Zealand. Patients are advised to consult with their doctor or pharmacist if they have concerns about their medication supply or alternative pain management options.
No comments:
Post a Comment